Skip to main content
MedPathMedPath Home
Clinical Trials/CTRI/2021/09/036891
CTRI/2021/09/036891
Not yet recruiting
Phase 2

A Prospective Open Label Interventional Study on the effect of Erandmooladi Niruh Basti and karpas tailum anuvasana basti in the Treatment of Amavata w.s.r. to Rheumatoid arthritis

Reetika Rana MD Student0 sites0 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsHealth Condition 1: M048- Other autoinflammatory syndromes

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Health Condition 1: M048- Other autoinflammatory syndromes
Sponsor
Reetika Rana MD Student
Status
Not yet recruiting
Last Updated
4 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional

Investigators

Sponsor
Reetika Rana MD Student

Eligibility Criteria

Inclusion Criteria

  • •1\. Patient suffering from classical sign and symptoms of Amavata as per madhavnidhan w.s.r. to Rheumatoid arthritis
  • •2\. Patient between 18 to 65 years.
  • •3\. Male and female patients willing and able to participate in the study.
  • •4\. Patient able to provide informed consent
  • •5\.Diagnosed patients of Rheumatoid arthritis as per ACR/EULAR.

Exclusion Criteria

  • •1\. Patient having chronicity more than 10 years.
  • •2\. Pregnant women and lactating women.
  • •3\. Patient having any other major complicated diseases like Piles, Diabetes mellitus,Cardiac diseases,Tuberculosis and AIDS.
  • •4\.Patient diagnosed with major systemic disorders that interfere with the course of treatment will be excluded from the study.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Not yet recruiting
Not Applicable
Intramuscular Ketamine use as an Antisuicidal drugHealth Condition 1: F322- Major depressive disorder, singleepisode, severe without psychotic features
CTRI/2022/09/045713I
Active, not recruiting
Phase 1
STRENSIQ® Immunogenicity StudyHYPOPHOSPHATASIAMedDRA version: 20.1Level: PTClassification code: 10049933Term: Hypophosphatasia Class: 100000004850Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]
CTIS2022-502793-17-00Alexion Pharmaceuticals Inc.8
Recruiting
Phase 2
The efficacy of anamorelin in patients with cachexia associated with chronic obstructive pulmonary diseasecachexia associated with chronic obstructive pulmonary diseasecachexiaD002100
JPRN-jRCTs031230446Ikari Jun28
Active, not recruiting
Phase 1
Vortioxetine in Patients With Depression Coexisting With General Anxiety Disorder (GAD)Depressive symptoms in patients with major depressive disorder (MDD) comorbid with generalized anxiety disorder (GAD)MedDRA version: 21.1Level: PTClassification code 10057840Term: Major depressionSystem Organ Class: 10037175 - Psychiatric disordersTherapeutic area: Psychiatry and Psychology [F] - Mental Disorders [F03]
EUCTR2019-001325-27-ESH. Lundbeck A/S102
Active, not recruiting
Phase 1
Vortioxetine in Patients With Depression Coexisting With General Anxiety Disorder (GAD)Depressive symptoms in patients with major depressive disorder (MDD) comorbid with generalized anxiety disorder (GAD)MedDRA version: 21.1Level: PTClassification code 10057840Term: Major depressionSystem Organ Class: 10037175 - Psychiatric disordersTherapeutic area: Psychiatry and Psychology [F] - Mental Disorders [F03]
EUCTR2019-001325-27-ITH. LUNDBECK A/S100